查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014625

痛風治療市場：2026-2032年全球市場預測（依給藥途徑、治療線、藥物類別及通路分類）

Gout Therapeutics Market by Route Of Administration, Therapy Line, Drug Class, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，痛風治療市場價值將達到 34 億美元，到 2026 年將成長至 37.8 億美元，到 2032 年將達到 75.8 億美元，複合年成長率為 12.13%。

主要市場統計數據
基準年 2025 34億美元
預計年份：2026年 37.8億美元
預測年份 2032 75.8億美元
複合年成長率 (%) 12.13%

這篇富有洞察力的引言概述了臨床複雜性、交付模式和治療方法創新如何重新定義相關人員對痛風治療的前景。

痛風治療的挑戰與臨床複雜性、患者依從性問題以及不斷發展的治療創新交織在一起。臨床醫生和行業領導者面臨著越來越大的期望，即在控制慢性高尿酸血症的同時，減輕急性發作，這加速了對細緻入微的戰略洞察的需求。近期科學的進步、醫療服務模式的變革以及支付方優先事項的改變，使得治療方法方案、給藥途徑和通路對患者療效和商業性成功都產生了深遠的影響。

這份文件清晰地介紹了痛風治療領域的主要變革性變化，包括生物製藥的引入、精確診斷和不斷發展的醫療保健服務模式。

在科學創新、臨床指南不斷更新以及患者期望不斷變化等因素的推動下，痛風的治療現狀正經歷著一場變革。首先，治療的演變以更加重視標靶生物製藥為特徵，尤其關注重組和聚乙二醇化尿酸酶製劑，它們為對傳統治療方法抗藥性的患者提供了新的治療選擇。這些藥物促使人們重新思考治療方案，並凸顯了注射給藥相比長期口服療法在操作上的顯著優勢。

對 2025 年美國實施的關稅措施可能對製造業、採購和市場進入動態產生的累積影響進行全面分析。

美國2025年推出的關稅政策對痛風藥物生態系統產生了多方面的影響，波及生產經濟、供應鏈結構和採購慣例。進口活性藥物成分、成品和專用醫療設備的關稅所帶來的成本壓力可能會增加製造商和契約製造的直接生產成本。面對這些壓力，製造商可能會尋求將部分生產環節遷回美國、實現供應商多元化，或重新談判長期契約，以保障利潤率並保持價格競爭力。

深入的細分分析揭示了路徑、治療線、藥物分類和分銷管道如何相互交織，並影響患者獲取藥物的機會和商業性成果。

細分市場的特定趨勢決定了藥物在給藥途徑、治療領域、藥物類別和分銷管道方面的臨床定位和商業性路徑。在考慮給藥途徑時，市場研究涵蓋注射和口服兩種途徑，其中注射劑可細分為靜脈注射和皮下注射。這種區分至關重要，因為靜脈注射劑型通常在受控的臨床環境中給藥，會影響住院患者的醫院利用率和藥房工作流程；而皮下注射劑型則可用於門診和居家給藥，從而改變支付方的保險覆蓋範圍和患者的用藥依從性。

重點區域洞察，檢驗主要地區的支付方框架、監管管道和醫療保健基礎設施如何影響痛風治療的可及性。

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、報銷框架和供應鏈策略。在美洲，由支付方主導的處方藥治療方法以及對真實世界療效證據的高度重視，正在影響傳統療法和新型治療方法的應用。尤其是在美國市場，私人保險公司、聯邦計畫和專科藥局仲介業者之間錯綜複雜的互動關係，影響著病患取得高成本注射和生物製藥的機會。在加拿大和拉丁美洲部分地區，報銷環境各不相同，集中採購和價格談判在治療方法的選擇中發揮重要作用。

提供切實可行的公司洞察，解釋主要企業如何最佳化其研發、供應鏈彈性和商業化策略，以在痛風治療市場中競爭。

痛風治療領域的企業策略著重於差異化的臨床特性、供應鏈韌性以及提供證據支持長期應用。領先的製藥和生物技術公司正在推廣結合成熟口服製劑和特殊注射製劑的產品組合，同時優先考慮擴大適應症、生命週期管理和患者支持項目。與專科藥房和醫院網路的合作簡化了靜脈和皮下注射生物製藥的分銷，而直接面向患者的分銷管道也擴大被用於支持口服療法在慢性疾病管理中的應用。

為行業領導者提供簡潔明了且切實可行的建議，以加強抵抗力，使證據的產生與支付方的需求保持一致，並最佳化痛風藥物的配銷通路。

產業領導者應採取務實且多管齊下的方法，在增強痛風治療全生命週期韌性的同時，最大限度地提高臨床價值。首先，他們應優先考慮靈活的生產結構和多元化的採購管道，以降低與地緣政治和關稅相關的風險，並將投資重點放在商業性可行的產能上。這些措施將減少跨國成本波動的影響，並使注射用生物製藥和複雜原料藥（API）的供應更具可預測性。

調查方法嚴格的混合方法，結合臨床醫師訪談、監管分析和供應鏈評估，確保得出可靠且檢驗的研究結果。

本分析的調查方法融合了定性和定量方法，旨在提供基於證據的、綜合性的臨床、商業和政策趨勢洞察。主要研究包括對臨床專業人員、醫院藥劑師、支付方代表和商業領域領導者進行結構化訪談，以收集關於治療方法定位、給藥途徑選擇和採購趨勢的第一手觀點。這些研究結果與監管文件、臨床指南和同行評審文獻進行了交叉比對，以確保其臨床準確性和情境相關性。

一份清晰明確的綜合分析報告，重點闡述了治療方法創新、支付方趨勢和營運韌性之間的相互作用，從而塑造了未來獲得痛風治療的機會。

總之，目前痛風治療的現狀受到多種因素的共同影響，例如治療創新、不斷演變的醫療服務模式以及政策壓力，所有這些因素共同影響治療的可及性和商業性趨勢。生物製藥（如尿酸酶療法）的出現以及給藥方法的改進為難治性痛風患者帶來了新的機遇，而口服藥物仍然是首選治療和長期管理的核心。通路和支付方框架對治療方法的採納和報銷有著顯著的影響，因此，針對具體情況制定商業化策略和實證醫學策略至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：痛風治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服

第9章：痛風治療市場（依治療系列分類）

  • 一線藥物
    • 非類固醇消炎劑
      • Ibuprofen
      • Indometacin
      • 萘普生
    • 黃嘌呤氧化酶抑制劑
      • Allopurinol
      • 非布司他
  • 二線藥物
    • 秋水仙鹼
    • 尿酸排泄促進劑
      • 苯溴馬龍
      • 雷辛納德
      • 丙磺舒
  • 三線藥物
    • 皮質類固醇
      • Methylprednisolone
      • 強的松
    • 尿酸分解酶製劑
      • 培格羅奇卡斯
      • 拉斯布里卡茲

第10章：痛風治療市場：依藥物類別分類

  • 抗發炎藥
    • 秋水仙鹼
    • 皮質類固醇
  • 尿酸酶製劑
    • 培格羅奇卡斯
    • 拉斯布里卡茲
  • 尿酸排泄促進劑
    • 苯溴馬龍
    • 雷辛納德
    • 丙磺舒
  • 黃嘌呤氧化酶抑制劑
    • Allopurinol
    • 非布司他
    • 托吡羅司他

第11章：痛風治療市場：依通路分類

  • 醫院藥房
    • 住院病人藥房
    • 門診藥房
  • 網路藥房
  • 零售藥房

第12章：痛風治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 痛風治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 痛風治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國痛風治療市場

第16章：中國痛風治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Arthrosi Therapeutics, Ltd.
  • AstraZeneca plc
  • Atom Therapeutics Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Horizon Therapeutics plc
  • Ironwood Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Olatec Therapeutics LLC
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Selecta Biosciences, Inc.
  • Sobi
  • Sun Pharmaceutical Industries Ltd.
  • Synlogic, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Teva Pharmaceutical Industries Ltd.
  • Urica Therapeutics, Inc.
Product Code: MRR-4349B3591E87

The Gout Therapeutics Market was valued at USD 3.40 billion in 2025 and is projected to grow to USD 3.78 billion in 2026, with a CAGR of 12.13%, reaching USD 7.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.40 billion
Estimated Year [2026] USD 3.78 billion
Forecast Year [2032] USD 7.58 billion
CAGR (%) 12.13%

An incisive introduction outlining how clinical complexity, delivery models, and therapeutic innovation are redefining the gout treatment landscape for stakeholders

The burden of gout therapeutics intersects clinical complexity, patient adherence challenges, and evolving therapeutic innovation. Clinicians and industry leaders face rising expectations to reduce acute flares while managing chronic hyperuricemia, and this environment has accelerated the need for nuanced strategic intelligence. Recent scientific advances, shifts in care delivery, and changing payer priorities have converged to create a landscape where therapeutic choices, route of administration, and distribution channels substantially influence patient outcomes and commercial success.

Against this background, the executive summary synthesizes critical developments across pharmacology, care pathways, and distribution. It places emphasis on the differentiation between oral and injectable modalities, the rising role of biologic uricase therapies, and the enduring relevance of traditional xanthine oxidase inhibitors and anti-inflammatory agents. In parallel, regulatory scrutiny and cost containment measures are reshaping procurement patterns in hospital and outpatient settings, while digital distribution channels are gaining traction among patients seeking convenience and privacy.

This introduction sets the stage for an evidence-based exploration of therapeutic segmentation, regional dynamics, and policy shocks that could materially alter access, pricing, and competitive positioning. It also frames a pragmatic set of recommendations for industry leaders seeking to optimize portfolio strategies, strengthen supply resilience, and align commercial models with evolving payer and provider expectations.

Clear articulation of the major transformative shifts in gout therapeutics including biologic adoption, precision diagnostics, and evolving care delivery models

The gout therapeutics landscape is undergoing transformative shifts driven by scientific innovation, evolving clinical guidelines, and changes in patient expectations. First, therapeutic evolution is characterized by a greater emphasis on targeted biologic approaches, most notably recombinant and pegylated uricase agents that offer treatment options for patients refractory to traditional therapies. These agents are driving reconsideration of therapy sequencing and highlighting the operational implications of injectable administration compared with longstanding oral regimens.

Concurrently, advances in precision medicine and biomarker-guided approaches are encouraging more individualized treatment regimens. This trend is reinforced by enhanced imaging and diagnostics that enable earlier detection of urate deposition and better tracking of therapeutic response, which in turn affects prescribing decisions and long-term disease management. In parallel, digital health tools and telemedicine are altering patient engagement, enabling remote monitoring and adherence support that can reduce acute flare rates and optimize therapy intensification when needed.

Additionally, supply chain modernization and strategic partnerships between manufacturers and specialty pharmacy channels are creating alternative access pathways for complex injectable treatments. These changes are complemented by payer policies that increasingly demand robust real-world evidence and value-based contracting, prompting manufacturers to demonstrate improved outcomes and cost offsets. Taken together, these shifts are reshaping competitive positioning, altering route-of-administration preferences, and encouraging greater emphasis on lifecycle management for both legacy and novel therapeutics.

Comprehensive analysis of the potential cumulative impacts of United States tariff measures introduced in 2025 on manufacturing, procurement, and market access dynamics

The United States tariff policies introduced in 2025 present a multifaceted set of implications for the gout therapeutics ecosystem, influencing manufacturing economics, supply chain configuration, and procurement practices. Tariff-induced cost pressures on imported active pharmaceutical ingredients, finished dosage forms, and specialized medical devices can increase direct production costs for manufacturers and contract manufacturers alike. Faced with these pressures, manufacturers may seek to re-shore certain operations, diversify supplier bases, or renegotiate long-term contracts to buffer margins and maintain price competitiveness.

These adjustments carry downstream effects for distribution and provider purchasing behavior. Hospitals and large integrated delivery networks that manage formularies and procurement at scale may respond to rising acquisition costs by intensifying cost containment measures, prioritizing therapies with clearer short-term cost offsets, or shifting utilization toward generics and established oral agents where clinical appropriateness allows. Meanwhile, specialty pharmacies and outpatient clinics that dispense injectable biologics will need to adapt inventory strategies and reimbursement navigation to lessen exposure to tariff-related volatility.

In addition, tariffs can slow the cadence of new product launches, particularly for smaller innovators reliant on global supplier networks for clinical supplies, analytical reagents, or complex device components. This potential slowdown may affect the availability of clinical trial materials and, in some cases, delay market entry timelines. However, the tariff environment also incentivizes strategic collaborations, such as localized manufacturing partnerships and co-investment in domestic capabilities, which can strengthen supply resiliency over the medium term. Ultimately, stakeholders with flexible sourcing strategies and adaptive pricing mechanisms will be better positioned to navigate the cumulative impacts of tariff policy changes.

Insightful segmentation analysis revealing how routes, therapy lines, drug classes, and distribution channels intersect to shape patient access and commercial outcomes

Segment-specific dynamics determine both clinical positioning and commercial pathways across routes of administration, therapy lines, drug classes, and distribution channels. When considering route of administration, the market is studied across injectable and oral approaches with injectables further subdivided into intravenous and subcutaneous modalities. This distinction matters because injectable intravenous formulations tend to be administered in controlled clinical settings with implications for hospital utilization and inpatient pharmacy workflows, whereas subcutaneous injectables facilitate outpatient or home-based administration, altering payer coverage constructs and patient adherence patterns.

Evaluating therapy line segmentation, the market is studied across first line, second line, and third line treatments. First-line strategies are examined across nonsteroidal anti-inflammatory drugs and xanthine oxidase inhibitors, with nonsteroidal agents further differentiated into ibuprofen, indomethacin, and naproxen. Xanthine oxidase inhibitors are explored in the context of allopurinol and febuxostat. Second-line options include colchicine and uricosuric agents, with the uricosuric category further analyzed for benzbromarone, lesinurad, and probenecid. Third-line considerations encompass corticosteroids and uricase agents, and corticosteroids are further examined through methylprednisolone and prednisone while uricase agents are contextualized with pegloticase and rasburicase. These layered therapy-line distinctions influence clinical algorithms, escalation thresholds, and formulary placement decisions.

From a drug class perspective, the market is studied across anti-inflammatory agents, uricase agents, uricosuric agents, and xanthine oxidase inhibitors. Anti-inflammatory agents are further analyzed through colchicine and corticosteroid subtypes. Within uricase and uricosuric categories, the clinical attributes of pegloticase, rasburicase, benzbromarone, lesinurad, and probenecid are evaluated with attention to efficacy in refractory populations, immunogenicity risks, and monitoring requirements. Xanthine oxidase inhibitors are considered across allopurinol, febuxostat, and topiroxostat, with differences in safety profiles and titration pathways highlighted.

Finally, distribution channel segmentation examines hospital pharmacy, online pharmacy, and retail pharmacy, with hospitals further divided into inpatient and outpatient pharmacies. Each channel presents distinct procurement cycles, reimbursement models, and patient interaction points. Hospital inpatient settings tend to prioritize acute administration protocols and formulary control, outpatient hospital pharmacies and retail pharmacies facilitate chronic management, and online pharmacies introduce convenience and discreet access. Together, these segmentation lenses provide a granular understanding of how therapeutic attributes, patient pathways, and commercial models intersect to shape uptake and long-term adherence.

Key regional insights examining how payer frameworks, regulatory pathways, and healthcare infrastructure across major geographies influence access to gout therapies

Regional dynamics shape clinical practice patterns, reimbursement frameworks, and supply chain strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, payer-driven formularies and a strong emphasis on evidence of real-world outcomes influence adoption of both legacy and novel therapies. The United States market in particular features complex interactions between private payers, federal programs, and specialty pharmacy intermediaries that affect patient access to high-cost injectables and biologics. Canada and parts of Latin America present diverse reimbursement landscapes where centralized procurement and negotiated pricing play significant roles in therapeutic selection.

Within Europe Middle East & Africa, regional heterogeneity is pronounced. Western European systems frequently leverage health technology assessment and national purchasing frameworks to determine access, favoring therapies with established cost-effectiveness data. Central and Eastern European markets may prioritize affordability and incremental access, which can slow uptake of newer biologic uricase agents. Middle Eastern markets display a mix of government-funded care and private provision, creating variable pathways for high-cost therapies. Across Africa, constrained healthcare budgets and limited specialty care infrastructure present access challenges, although tiered distribution strategies and donor-supported programs can enable targeted interventions.

Asia-Pacific markets demonstrate rapid innovation adoption in certain high-income economies, with strong local manufacturing footprints and a rising interest in biosimilars and domestically developed agents. Emerging economies within the region often prioritize essential oral therapies and low-cost generics, while larger metropolitan centers increasingly adopt advanced injectable therapies through specialty clinics and tertiary hospitals. Across all regions, logistics complexity, regulatory timelines, and local clinical guidelines drive differentiated access strategies that manufacturers must navigate with tailored market-entry and commercialization plans.

Actionable corporate insights describing how leading firms are optimizing R&D, supply resilience, and commercialization strategies to compete in the gout therapeutics arena

Company strategies in the gout therapeutics space are focusing on differentiated clinical profiles, supply chain resilience, and evidence generation to support long-term uptake. Leading pharmaceutical and biotech companies are advancing portfolios that blend established oral agents with specialty injectables, while prioritizing label expansions, lifecycle management, and patient support programs. Partnerships with specialty pharmacies and hospital networks enable streamlined distribution for intravenous and subcutaneous biologics, while direct-to-patient distribution channels are increasingly used to support chronic management with oral therapies.

Strategic R&D investments emphasize improving safety profiles, simplifying administration, and addressing gaps in refractory patient populations where uricase agents have demonstrated clinical value. Licensing deals and co-development arrangements are tools for accelerating access to formulation innovations and novel delivery devices, particularly when localized manufacturing or regulatory expertise is required. Commercially, companies are investing in payer engagement and health economic modeling to substantiate value propositions and secure favorable reimbursement pathways, especially for high-cost injectable therapies.

Operational competencies that distinguish successful companies include robust pharmacovigilance frameworks, scalable manufacturing for both small-molecule APIs and biologics, and flexible distribution models that can pivot between hospital, retail, and online channels. Additionally, firms that effectively integrate digital patient support, adherence interventions, and clinician education initiatives tend to achieve stronger persistence and better real-world outcomes, thereby reinforcing payer and provider confidence in their therapeutic offerings.

Concise and actionable recommendations for industry leaders to strengthen resilience, align evidence generation with payer needs, and optimize commercial channels for gout therapies

Industry leaders should adopt a pragmatic, multi-pronged approach to capture clinical value while strengthening resilience across the gout therapeutics lifecycle. First, prioritize flexible manufacturing and diversified sourcing to mitigate geopolitical and tariff-related risks, with targeted investments in regional production capacity where commercially viable. Such initiatives reduce exposure to cross-border cost shocks and enable more predictable supply for injectable biologics and complex APIs.

Second, align evidence generation with payer expectations by expanding real-world evidence initiatives and designing post-approval studies that demonstrate outcomes meaningful to providers and payers. Real-world safety and effectiveness data are essential to support value-based contracting, which can facilitate access for high-cost therapies. Third, refine commercial models by differentiating distribution strategies: optimize hospital formulary engagement for inpatient-administered treatments, nurture specialty pharmacy partnerships for outpatient injectables, and scale online pharmacy capabilities for improved patient convenience and privacy.

Fourth, enhance patient-centric offerings with adherence support, remote monitoring, and educational resources that reduce flare frequency and improve long-term disease control. Fifth, pursue tactical label enhancements and indication expansions where clinical data support broader use, while ensuring rigorous risk management practices for immunogenicity-prone biologics. Finally, cultivate strategic collaborations with payers, providers, and technology partners to advance integrated care pathways that align clinical benefits with cost containment objectives and deliver predictable outcomes across diverse healthcare systems.

Rigorous mixed-methods research methodology combining clinician interviews, regulatory analysis, and supply chain assessment to ensure robust and validated insights

The research methodology underpinning this analysis integrates qualitative and quantitative techniques to provide an evidence-based synthesis of clinical, commercial, and policy trends. Primary research comprised structured interviews with clinical specialists, hospital pharmacists, payer representatives, and commercial leaders to capture firsthand perspectives on therapy positioning, administration preferences, and procurement dynamics. These insights were triangulated with regulatory documentation, clinical guidelines, and peer-reviewed literature to ensure clinical accuracy and contextual relevance.

Secondary research reviewed public filings, regulatory announcements, product labels, and scientific conference disclosures to build a comprehensive view of therapeutic mechanisms, safety considerations, and trial endpoints. The study also incorporated supply chain and distribution channel analyses, including assessments of manufacturing footprints, logistics vulnerabilities, and specialty pharmacy operational models. Throughout the research process, emphasis was placed on cross-validating data from multiple sources to minimize bias and enhance the robustness of conclusions.

Analytical techniques included comparative clinical attribute mapping, therapy-line pathway analysis, and scenario-based impact assessment to evaluate potential operational and commercial effects of policy changes such as tariffs. Sensitivity checks and expert validation workshops were employed to refine interpretations and ensure that recommendations are operationally feasible and aligned with stakeholder needs.

Clear and conclusive synthesis highlighting the interplay between therapeutic innovation, payer dynamics, and operational resilience that will shape future access to gout treatments

In conclusion, the gout therapeutics landscape is characterized by an interplay of therapeutic innovation, shifting care delivery models, and policy pressures that collectively influence access and commercial dynamics. The emergence of biologic uricase therapies and refined administration options creates new opportunities for patients with refractory disease, while oral agents remain central to first-line management and long-term control. Distribution channels and payer frameworks materially affect how therapies are adopted and reimbursed, making tailored commercialization and evidence strategies essential.

Stakeholders that proactively strengthen supply resilience, invest in real-world evidence, and customize distribution approaches to regional nuances will be better positioned to capture clinical and commercial value. Moreover, careful navigation of tariff-related disruptions and strategic partnerships for localized manufacturing can mitigate exposure to cost shocks while accelerating patient access. Ultimately, translating clinical advances into sustained health outcomes will require integrated efforts across manufacturers, providers, payers, and patient advocates to align incentives and operational capabilities in service of improved care for people living with gout.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gout Therapeutics Market, by Route Of Administration

  • 8.1. Injectable
    • 8.1.1. Intravenous
    • 8.1.2. Subcutaneous
  • 8.2. Oral

9. Gout Therapeutics Market, by Therapy Line

  • 9.1. First Line
    • 9.1.1. Nonsteroidal Anti-Inflammatory Drug
      • 9.1.1.1. Ibuprofen
      • 9.1.1.2. Indomethacin
      • 9.1.1.3. Naproxen
    • 9.1.2. Xanthine Oxidase Inhibitor
      • 9.1.2.1. Allopurinol
      • 9.1.2.2. Febuxostat
  • 9.2. Second Line
    • 9.2.1. Colchicine
    • 9.2.2. Uricosuric Agent
      • 9.2.2.1. Benzbromarone
      • 9.2.2.2. Lesinurad
      • 9.2.2.3. Probenecid
  • 9.3. Third Line
    • 9.3.1. Corticosteroid
      • 9.3.1.1. Methylprednisolone
      • 9.3.1.2. Prednisone
    • 9.3.2. Uricase Agent
      • 9.3.2.1. Pegloticase
      • 9.3.2.2. Rasburicase

10. Gout Therapeutics Market, by Drug Class

  • 10.1. Anti-Inflammatory Agent
    • 10.1.1. Colchicine
    • 10.1.2. Corticosteroid
  • 10.2. Uricase Agent
    • 10.2.1. Pegloticase
    • 10.2.2. Rasburicase
  • 10.3. Uricosuric Agent
    • 10.3.1. Benzbromarone
    • 10.3.2. Lesinurad
    • 10.3.3. Probenecid
  • 10.4. Xanthine Oxidase Inhibitor
    • 10.4.1. Allopurinol
    • 10.4.2. Febuxostat
    • 10.4.3. Topiroxostat

11. Gout Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
    • 11.1.1. Inpatient Pharmacy
    • 11.1.2. Outpatient Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gout Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gout Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gout Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gout Therapeutics Market

16. China Gout Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Arthrosi Therapeutics, Ltd.
  • 17.8. AstraZeneca plc
  • 17.9. Atom Therapeutics Co., Ltd.
  • 17.10. Boehringer Ingelheim International GmbH
  • 17.11. Dr. Reddy's Laboratories Ltd.
  • 17.12. Eli Lilly and Company
  • 17.13. GlaxoSmithKline plc
  • 17.14. Horizon Therapeutics plc
  • 17.15. Ironwood Pharmaceuticals, Inc.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Olatec Therapeutics LLC
  • 17.19. Pfizer Inc.
  • 17.20. Protalix BioTherapeutics, Inc.
  • 17.21. Regeneron Pharmaceuticals, Inc.
  • 17.22. Selecta Biosciences, Inc.
  • 17.23. Sobi
  • 17.24. Sun Pharmaceutical Industries Ltd.
  • 17.25. Synlogic, Inc.
  • 17.26. Takeda Pharmaceutical Company Limited
  • 17.27. Teijin Pharma Limited
  • 17.28. Teva Pharmaceutical Industries Ltd.
  • 17.29. Urica Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 305. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 318. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 319. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
  • TABLE 320. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
  • TABLE 322. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 323. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 325. GCC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 326. GCC GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 327. GCC GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 328. GCC GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)

T